United Kingdom — For men experiencing bothersome urinary symptoms due to benign prostatic hyperplasia (BPH) — commonly known as an enlarged prostate — Aquablation therapy is emerging as a promising, minimally invasive surgical option that addresses both symptom burden and quality of life.
BPH affects a significant proportion of the male population, particularly those over age 50, and can lead to frequent urination, weak urinary stream, nocturia, urgency and a sensation of incomplete bladder emptying. These symptoms often compromise daily functioning and overall well-being.
Aquablation therapy uses a robotically guided, high-pressure water jet combined with real-time imaging to precisely remove excess prostate tissue responsible for obstruction — all without using heat. This heat-free mechanism enables accurate tissue resection while preserving surrounding structures important for continence and sexual function.
Unlike traditional surgical approaches that may have size limitations or higher risk profiles, Aquablation has been shown to be effective across a wide range of prostate sizes and shapes, making it a versatile option for a broad spectrum of patients.
Clinical outcomes continue to support the procedure’s long-term durability, with studies demonstrating significant and sustained improvement in urinary symptoms and flow metrics, as well as a favourable safety profile.
Urology specialists note that Aquablation can be particularly valuable for men who have not found adequate relief from medications or who are seeking an alternative to more invasive surgery. Its precision, reduced risk of irreversible complications such as incontinence, and its adaptability across prostate sizes position it as an important addition to contemporary BPH treatment pathways.
As awareness of new surgical technologies grows, Aquablation therapy is fast becoming a standard consideration for men looking to regain comfort and quality of life from the effects of an enlarged prostate.
